



## Company Overview

SINTX Technologies is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. SINTX markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. The company operates an ISO 13485 certified manufacturing facility and its spine products are FDA registered and ISO 13485:2016 certified, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.

## Stock Overview

Symbol	SINT
Exchange	Nasdaq
Market Cap	43.93m
Last Price	\$1.79
52-Week Range	\$0.28 - \$3.30

09/28/2020 04:00 PM EDT

## Investor Relations

T: 801-839-3502  
[IR@sintx.com](mailto:IR@sintx.com)

## Management Team

### B. Sonny Bal, MD, JD, MBA, PhD

Chairman of the Board, Chief Executive Officer,  
President & Principal Financial Officer

### Bryan J. McEntire, MBA, PhD

Chief Scientific Officer

### David O'Brien

Chief Operating Officer

### Donald J. Bray

Vice President of Business Development

## SINTX Technologies, Inc.

1885 West 2100 South  
Salt Lake City, UT 84119

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.